Charles S. Berkman Sells 25,489 Shares of OmniAb, Inc. (NASDAQ:OABI) Stock

OmniAb, Inc. (NASDAQ:OABI) insider Charles S. Berkman sold 25,489 shares of the stock in a transaction on Tuesday, January 21st. The stock was sold at an average price of $3.24, for a total transaction of $82,584.36. Following the sale, the insider now owns 343,190 shares of the company’s stock, valued at approximately $1,111,935.60. This represents a 6.91 % decrease in their position. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available through this link.

OmniAb Price Performance

Shares of OmniAb stock opened at $3.20 on Friday. The firm has a market cap of $451.89 million, a price-to-earnings ratio of -5.16 and a beta of -0.10. OmniAb, Inc. has a 52-week low of $3.11 and a 52-week high of $6.55. The company’s 50-day simple moving average is $3.66 and its 200-day simple moving average is $4.06.

Hedge Funds Weigh In On OmniAb

A number of large investors have recently modified their holdings of OABI. Barclays PLC boosted its stake in shares of OmniAb by 321.5% in the third quarter. Barclays PLC now owns 143,215 shares of the company’s stock valued at $606,000 after buying an additional 109,236 shares in the last quarter. FMR LLC boosted its position in shares of OmniAb by 10.6% during the 3rd quarter. FMR LLC now owns 138,813 shares of the company’s stock worth $587,000 after purchasing an additional 13,324 shares in the last quarter. Atria Investments Inc purchased a new stake in shares of OmniAb during the 3rd quarter worth $148,000. Murchinson Ltd. acquired a new position in shares of OmniAb during the 3rd quarter worth $4,230,000. Finally, State Street Corp increased its holdings in shares of OmniAb by 1.7% in the 3rd quarter. State Street Corp now owns 2,031,676 shares of the company’s stock valued at $8,594,000 after purchasing an additional 34,654 shares in the last quarter. 72.08% of the stock is owned by hedge funds and other institutional investors.

Analyst Upgrades and Downgrades

A number of brokerages have recently commented on OABI. HC Wainwright reaffirmed a “buy” rating and issued a $11.00 target price on shares of OmniAb in a report on Thursday, November 14th. Benchmark reaffirmed a “buy” rating and set a $8.00 price objective on shares of OmniAb in a research report on Thursday, November 14th.

OmniAb Company Profile

OmniAb, Inc, a biotechnology company, engages in the discovery and provision of therapeutic antibody discovery technologies in the United States. The company's technology platform creates and screens diverse antibody repertoires and identify optimal antibodies for partners' drug development efforts.